Results 111 to 120 of about 41,710 (302)
Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options
Dipeptidyl peptidase 4 inhibitors are a new innovative class of glucose-lowering drugs. The drugs belong to the group of incretin mimetics, prolonging the action of their own incretins. Since 2007, the list of proposed dipeptidyl peptidase 4 inhibitors has expanded significantly and significant experience in their use has accumulated.
S.V. Podachina, I.V. Soloviova
openaire +1 more source
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are widely used for managing Type 2 diabetes and obesity, with well‐documented and significant cardiometabolic benefits. Recent observational reports and pharmacovigilance data have raised concerns about a possible association between GLP‐1RAs‐particularly semaglutide‐ and non‐arteritic ...
Helen V. Danesh‐Meyer +1 more
wiley +1 more source
Aims/Introduction The present study investigated the effect of high‐dose metformin or low‐dose metformin/linagliptin combination therapy on glycemic variability (GV) in type 2 diabetes patients with insufficient glycemic control despite low‐dose ...
Hiroshi Takahashi +3 more
doaj +1 more source
Summary Background Bariatric surgery is very effective in long‐term weight management. The present study was undertaken to investigate the short‐term effects of sleeve gastrectomy (SG) and of Roux‐en‐Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro‐cecal transit time and (b) secretion of regulatory gut ...
Jennifer A. Wilbrink +4 more
wiley +1 more source
Health economic evaluation of dipeptidyl peptidase-4 inhibitors
Sir, The predicted loss of national income from diabetes in India is 336.6 billion International Dollars.[1] Furthermore, studies have demonstrated that the prevalence of diabetes in India is rising with the progression of time.[2] Therefore, this financial burden is bound to increase.
openaire +3 more sources
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang +5 more
wiley +1 more source
Sulphostin-inspired N-phosphonopiperidones as selective covalent DPP8 and DPP9 inhibitors
Covalent chemical probes and drugs combine unique pharmacologic properties with the availability of straightforward compound profiling technologies via chemoproteomic platforms.
Leonard Sewald +12 more
doaj +1 more source
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
Lin Chen,1,* Xiujuan Zhang,2,* Li Zhang,3 Dongmei Zheng2 1Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China; 2Department of ...
Chen L, Zhang X, Zhang L, Zheng D
doaj
Efecto inhibitorio de un extracto acuoso de las hojas de Allophylus cominia (L.) Sw sobre las proteínas tirosina fosfatasa 1B y dipeptidil peptidasa IV [PDF]
Introduction: Allophylus cominia (L.) Sw is a Cuban medicinal plant used by traditional medicine for the treatment of diabetes with unknown mechanisms of action.
L. Harvey, Alan +3 more
core
Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
The pharmacological actions of the glucagon-like peptide-1 receptor agonists (GLP-1RA) are largely predictable as they interact directly with GLP-1 receptors on beta cells to mediate their glucose lowering effects by increasing GLP-1 in pharmacological range and not at all dependent upon endogenous GLP-1 secretion. The mechanism of action of dipeptidyl
openaire +3 more sources

